Genetic risk factors of atherothrombosis

Montagnana, Martina; Danese, Elisa; Lippi, Giuseppe

doi:10.20452/pamw.2409

Cited by 16 publications

(16 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the panel of polymorphisms examined in this study is by no means exhaustive and there is no doubt that multi-factorial disorders, such as the vast majority of strokes or CHD, are most probably related to an interplay between a multitude of other genetic, epigenetic and environmental factors [32]. It would therefore appear that the introduction of similar studies as a useful tool in everyday clinical practice may still be premature [33], and perhaps the main value of these approaches in the immediate future is not to provide predictive genetic testing, which may currently yield limited information, but instead to afford a better understanding of the underlying disease mechanisms.…”

Section: Discussionmentioning

confidence: 99%

The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers

Konialis¹,

Spengos

Iliopoulos³

et al. 2016

Adv Clin Exp Med

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers

Konialis¹,

Spengos

Iliopoulos³

et al. 2016

Adv Clin Exp Med

View full text Add to dashboard Cite

“…Less commonly inherited thrombophilia is observed in patients with myocardial infarction or ischemic stroke [9].…”

Section: Inherited Thrombophiliamentioning

confidence: 99%

Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment

Undas

Góralczyk

2016

Adv Clin Exp Med

View full text Add to dashboard Cite

“…The safety and efficacy of rivaroxaban as compared with aspirin, in addition to a single antiplatelet P2Y 12 inhibitor – clopidogrel or ticagrelor – in subjects with a recent STEMI or NSTEMI are being tested in the ongoing GEMINI trial. There is also no evidence that prothrombotic genetically determined factors might affect the efficacy or safety of NOAC used in monotherapy or combination [71]. …”

Section: Future Perspectives For Noac After Acsmentioning

confidence: 99%

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation

Zalewski¹,

Undas²

2016

pwki

View full text Add to dashboard Cite

The dynamic evolution of therapeutic options including the use of vitamin K antagonists (VKA), non-vitamin K oral anticoagulants (NOAC), more potent antiplatelet drugs as well as new generation drug-eluting stents could lead to the view that the current recommendations on the management of patients with percutaneous coronary intervention (PCI) requiring oral anticoagulation do not keep up with the results of several clinical studies published within the last 5 years. In the present overview, we summarize the recent advances in antithrombotic management used in atrial fibrillation patients undergoing PCI for stable coronary artery disease or acute coronary syndrome (ACS). The safety and efficacy of prasugrel and ticagrelor taken with oral anticoagulants also remain to be established in randomized trials; therefore the P2Y12 inhibitor clopidogrel on top of aspirin or without is now recommended to be used together with a VKA or NOAC. It is still unclear which dose of a NOAC in combination with antiplatelet agents and different stents should be used in this clinical setting and whether indeed NOAC are safer compared with VKA in such cardiovascular patients. Moreover, we discuss the use of anticoagulation in addition to antiplatelet therapy for secondary prevention in patients with ACS. To minimize bleeding risk in anticoagulated patients following PCI or ACS, the right agent should be prescribed to the right patient at the right dose and supported by regular clinical evaluation and laboratory testing, especially assessment of renal function when a NOAC is used.

show abstract

Genetic risk factors of atherothrombosis

Cited by 16 publications

References 52 publications

The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers

The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers

Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation

Contact Info

Product

Resources

About